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Background
Darunavir and fos-amprenavir share similar in vitro
suceptibility patterns. Whether previous failure with fos-
amprenavir leads to impaired response to darunavir
remains an open question.
Methods
We evaluated week 48 response to a darunavir-containing
regimen in patients who previously failed on fos-ampre-
navir.
Summary of results
17 patients (pts) fulfilling the selection criteria were
retrieved from our database. They had been exposed to a
median of six NRTIs, one NNRTI and seven PIs (five pts
being tipranavir experienced). Median baseline plasma
HIV-RNA was 5,775 copies/ml and median CD4 count
was 200 cells/mm3. Median number of IAS protease
mutations was 11 (IQR 9–12), median number of daru-
navir mutations was one (range 0–4). 14/17 p (82%) were
genotypically resistant to fos-amprenavir. The new regi-
men included enfuvirtide (16 pts), etravirine (10 pts),
raltegravir (four pts) and maraviroc (two pts).
At week 48, VL below 50 copies/ml was obtained in 9/17
pts (53%). Among the eight pts who failed on darunavir,
seven had no major mutation for darunavir at baseline,
the remaining pt had one major mutation. No correlation
was found between virological response at week 48 and
baseline characteristics such as number of mutations for
fos-amprenavir, treatment history, and other ARV drugs in
the new regimens. Of note, enfuvirtide was used for the
first time in 6/9 responding pts vs. 3/8 in the failing pts.
Conclusion
Our data suggest that prior failure on fos-amprenavir has
limited impact on response to darunavir and that fos-
amprenavir selected key mutations have low impact on
DRV virological response
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